Time to Discontinuation of Tofacitinib and TNF inhibitors in Rheumatoid Arthritis Patients with and without Methotrexate: **Results From The Ontario Best Practices Research Initiative (OBRI)**

¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON; ² Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, ON; ³ Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON; ⁴Department of Medicine (DOM) and Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, ON

BACKGROUND

Tofacitinib (TOFA) is an oral, small molecule drug which can be used as an alternative to biologic disease modifying antirheumatic drugs (bDMARDs) including tumor necrosis factor inhibitors (TNFi) for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX).

OBJECTIVES

We aimed to evaluate the discontinuation rate of TOFA, with and without concurrent MTX, in comparison with TNFi, in patients with RA in the Ontario Best Practices Research Initiative (OBRI); a clinical registry (OBRI-RA registry) following RA patients in routine care in Ontario-Canada (www.obri.ca).

METHODS

- RA patients enrolled in the OBRI initiating their TOFA or TNFi (adalimumab, certolizumab, etancercept, golimumab, and infliximab) within 30 days prior to or anytime after enrolment between 1st Jun 2014 (TOFA approval date in Canada) and 31st Dec 2018 were included. Patients were excluded if they had < 2 visits and < 6 months follow-up.
- Time to discontinuation (due to any reason) was assessed using Kaplan-Meier survival, adjusted for propensity score using inverse probability of treatment weight (IPTW), to compare patients with and without MTX use at initiation of TOFA or TNFi.
- Covariates used for estimating propensity score: age, sex, education, annual household income, health insurance coverage, RA disease duration, number of prior biologic use, CDAI, rheumatoid factor, HAQ-DI, ESR, the presence of comorbidity (cancer, hypertension, CVD, diabetes mellitus, lung disease, depression, osteoarthritis), prior use of csDMARDs, and current use of other csDMARDs.
 - To deal with missing data, Markov Chain Monte Carlo (MCMC) was used for multiple imputation (n=20) assuming that all variables in the imputation model have a joint multivariate normal distribution (MVN).

OBRI Investigators: Drs. Ahluwalia, V., Ahmad, Z., Akhavan, P., Albert, L., Alderdice, C., Aubrey, M., Aydin, S., Bobba, R., Bookman, A., Cabral, A., Carette, S., Carmona, R., Chow, A., Chow, S., Choy, G., Ciaschini, P., Cividino, A., Cohen, D., Dixit, S., Haaland, D., Hanna, B., Haroon, N., Hochman, J., Jaroszynska, A., Karsh, J., Keystone, E., Khalidi, N., Kuriya, B., Larche, M., Lau, A., LeRiche, N., Leung, Fe., Leung, Fr., Mahendira, D., Matsos, M., McDonald-Blumer, McKeown, E., Midzic, I., Milman, N., H., Mittoo, S., Mody, A., Montgomery, A., Montgomery, A., Mulgund, M., Ng, E., Papneja, T., Pavlova, P., Perlin, L., Pope, J., Purvis, J., Rohekar, G., Rohekar, G., Rohekar, S., Ruban, T., Samadi, N., Sandhu, S., Shaikh, S., Shickh, A., Shupak, R., Smith, D., Soucy, E., Stein, J., Thompson, A., Thorne, C., Wilkinson, S.

Mohammad Movahedi^{1,2}, Angela Cesta¹, Xiuying Li¹, Edward Keystone³, Claire Bombardier^{1,3,4} and OBRI investigators

RESULTS

- (9.4) years.
- In the TOFA group, 86% were female and mean (SD) age at treatment age (SD) was 57.0 (12.6) years.
 - with the TNFi group (31.0%).
 - patients with and without MTX (Logrank p=0.31) (Figure 1).

Table 1: Patient Profile at Initiation of TOFA or TNFi With and Without MTX


	TOFA			TNFi		
	MTX+ (n=106)	MTX- (n=102)	P-value	MTX+ (n=222)	MTX- (n=135)	P-value
Disease Duration At Treatment Initiation (years)	13.2 ± 9.6	13.0 ± 9.4	0.87	9.5 ± 9.4	9.8 ± 9.4	0.74
Age At Treatment Initiation (years)	60.5 ± 9.9	60.3 ± 11.2	0.89	57.2 ± 12.1	56.5 ± 13.4	0.62
Nomen	88 (83.0%)	91 (89.2%)	0.20	173 (77.9%)	120 (88.9%)	0.01
Concomitant MTX Start Dose	18.2± 6.3			18.6 ± 5.9		
Main Comorbidity Number	1.9 ± 2.1	2.3 ± 2.1	0.13	1.7 ± 1.9	1.9 ± 2.0	0.42
Positive Rheumatoid Factor	69 (70.4%) (N=98)	71 (77.2%) (N=92)	0.29	164 (79.2%) (N=207)	91 (71.0%) (N=128)	0.07
Positive Anti–Citrullinated Protein Antibody	28 (63.6%) (N=44)	22 (53.7%) (N=41)	0.35	82 (70.7%) (N=116	41(61.2%) (N=67	0.19
Clinical Disease Activity Index	25.3 ± 11.6 (N=90)	24.2 ± 12.7 (N=81)	0.99	20.8 ± 11.9 (N=170)	22.5 ± 12.1 (N=96)	0.08
Freatment Stopped	39 (36.8%)	36 (35.3%)	0.82	58 (26.1%)	45 (33.3%)	0.15
 Treatment Duration (years) 	0.58 ± 0.4 (N=39)	0.51 ± 0.5 (N=36)	0.52	1.0 ± 0.7 (N=58)	0.8 ± 0.8 (N=45)	0.17
Reason for Treatment Cessation			0.99			0.39
 Ineffectiveness 	15 (38.5%)	14 (38.9%)		28 (48.3%)	16 (35.6%)	
 Adverse Event 	16 (41.0%)	15 (41.7%)		11 (19.0%)	9 (20.0%)	
 Other 	8 (20.5%)	7 (19.4%)		19 (32.8%)	20 (44.4)	
Freatment Ongoing	67 (63.2%)	66 (64.7%)	0.82	164 (73.9%)	90 (66.7%)	0.15
 Treatment Duration (years) 	1.3 ± 0.9 (N=67)	1.4 ± 1.1 (N=66)	0.61	1.9 ± 1.2 (N=164)	1.9 ± 1.1 (N=90)	0.57
Treatment Selection						
First Agent	42 (39.6%)	38 (37.3%)	0.73	168 (75.7%)	78 (57.8%)	<0.001
Subsequent Agent	64 (60.4%)	64 (62.7%)		54 (24.3%)	57 (42.2%)	


A total of 565 patients initiated TOFA (n=208) or TNFi (n=357). Of those, 106 (51%) and 222 (62%) were treated with MTX in the TOFA and TNFi group, respectively (Table 1) and mean (SD) disease duration were 13.1 (9.4) and 9.5

initation was 60.4 (10.6) years. In the TNFi group 82% were female and mean

The TOFA group was more likely to have prior biologic use (61.5%) compared

After adjusting for propensity score, patients treated with TNFi and MTX remained on treatment longer than those treated without MTX (Logrank p=0.002) while there was no significant difference in TOFA discontinuation in





CONCLUSIONS

Funding: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Janssen, Medexus, Merck, Novartis, and Pfizer. Acknowledgment: Dr. Bombardier held a Canada Research Chair in Knowledge Transfer for Musculoskeletal Care and a Pfizer Research Chair in Rheumatology **Correspondence to:** OBRI at: <u>obri@uhnresearch.ca</u>





Figure 1: Propensity Score Weighted (IPTW) Kaplan-Meier Survival Curves for Time to **Discontinuation of TOFA or TNFi With MTX and Without MTX**

• In this real world data study, we found that TOFA retention is similar in patients with and without MTX, while patients treated with TNFi and MTX remained on treatment longer than those treated without MTX.

Merging data with other RA registries in Canada is proposed to increase study power and to provide more robust results.











